BRIEF-GSK gets Canadian approval for bronchodilator treatment Incruse

Thu Apr 17, 2014 11:35am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

April 17 (Reuters) - Glaxosmithkline Plc :

* Glaxosmithkline plc gsk receives approval in Canada for incruse

* Announces approval in canada for Incruse Ellipta (Umeclidinium) as a treatment for COPD

* Has received market authorisation in Canada for long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema

* Clinical programme for Umeclidinium included seven phase iii clinical trials which involved over 2,500 copd patients treated with umeclidinium or placebo Source text for Eikon: Further company coverage: